| 1 |
Buijs C, Mom CH, Willemse PH, et al., Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 2009; 115: 573-580.
DOI
ScienceOn
|
| 2 |
Walker EM, Rodriguez AI, Kohn B, et al., Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 2010; 28: 634-640.
DOI
ScienceOn
|
| 3 |
 prescribing information. Wyeth Pharmaceuticals. 2009.
|
| 4 |
Venlafaxine hydrochloride. In: AHFS Drug Information. American Society of Health-System Pharmacists. 2010.
|
| 5 |
Venlafaxine. In: Drug Information Handbook. Lexi- . 2008.
|
| 6 |
Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000; 57: 503-509.
DOI
ScienceOn
|
| 7 |
Loprinzi CL, Levitt R, Barton D, et al., Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 2006; 24: 1409-1414.
DOI
ScienceOn
|
| 8 |
Tran PV, Bymaster FP, McNamara RK, et al., Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003; 23: 78-86.
DOI
ScienceOn
|
| 9 |
Loprinzi CL, Kugler JW, Sloan JA, et al., Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356: 2059-2063.
DOI
ScienceOn
|
| 10 |
Evans ML, Pritts E, Vittinghoff E, et al., Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005; 105: 161-166.
DOI
ScienceOn
|
| 11 |
Carpenter JS, Storniolo AM, Johns S, et al., Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 2007; 12: 124-135.
DOI
|
| 12 |
Loibl S, Schwedler K, von Minckwitz G, et al., Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. Ann Oncol 2007; 18: 689-693.
|
| 13 |
Rossouw JE, Anderson GL, Prentice RL, et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
DOI
ScienceOn
|
| 14 |
Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000; 36: 155-164.
DOI
ScienceOn
|
| 15 |
Mohyi D, Tabassi K, Simon J. Differential diagnosis of hot flashes. Maturitas 1997; 27: 203-214.
DOI
ScienceOn
|
| 16 |
Kronenberg F, Downey J. Thermoregulatory physiology of menopausal hot flashes. Canadian J Physiol Pharmacol 1987; 65: 1312-1322.
DOI
ScienceOn
|
| 17 |
Lomax P, Schonbaum E. Postmenopausal hot flushes and their management. Pharm Ther 1993; 57: 347-358.
DOI
|
| 18 |
Freedman RR, Woodward S, Sabharwal SC. Alpha 2-adrenergic mechanism in menopausal hot flushes. Obstet Gynecol 1990; 76: 573-578.
|
| 19 |
Irani J, Salomon L, Oba R, et al., Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010; 11: 147-154.
DOI
ScienceOn
|
webmaster
